We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$579M
Cap. Flow %
7.9%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 41.39%
2 Healthcare 39.34%
3 Consumer Discretionary 6.39%
4 Consumer Staples 5.37%
5 Technology 5.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.4B
$1.5B 20.5%
6,800,000
+1,600,000
+31% +$365M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$812B
$1.47B 19.99%
2,500,000
+500,000
+25% +$295M
PTCT icon
3
PTC Therapeutics
PTCT
$5.75B
$288M 3.93%
6,378,000
-856,898
-12% -$36.7M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.47B
$175M 2.39%
4,836,000
-260,000
-5% -$9.16M
TVTX icon
5
Travere Therapeutics
TVTX
$6.11B
$128M 1.75%
7,358,000
-290,000
-4% -$5.13M
INCY icon
6
Incyte
INCY
$25.4B
$122M 1.67%
1,767,830
-428,275
-20% -$30.5M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.9B
$122M 1.66%
892,000
+710,619
+392% +$87.9M
IMVT icon
8
Immunovant
IMVT
$8.23B
$95.9M 1.31%
3,870,586
+322,586
+9% +$9.15M
EXAS
9
DELISTED
Exact Sciences
EXAS
$90.9M 1.24%
+1,617,000
New +$101M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$134B
$90.2M 1.23%
224,016
+177,887
+386% +$82.5M
ICLR icon
11
Icon
ICLR
$12.4B
$87.7M 1.2%
+418,112
New +$97.6M
GSK icon
12
GSK
GSK
$97.5B
$80.4M 1.1%
2,378,000
+1,854,000
+354% +$66.7M
FIVN icon
13
FIVE9
FIVN
$2.36B
$80.1M 1.09%
1,970,207
+94,207
+5% +$3.4M
NARI
14
DELISTED
Inari Medical, Inc. Common Stock
NARI
$79.9M 1.09%
1,565,577
-256,423
-14% -$12.6M
HUM icon
15
Humana
HUM
$48.7B
$79.2M 1.08%
312,000
+133,915
+75% +$35.9M
ARGX icon
16
argenx
ARGX
$63.2B
$76.3M 1.04%
124,000
-28,000
-18% -$16.4M
GRFS
17
Grifois
GRFS
$5.29B
$74.7M 1.02%
10,036,000
+500,000
+5% +$4.17M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.01B
$74.4M 1.02%
2,264,304
+57,234
+3% +$2.69M
BUD icon
19
AB InBev
BUD
$157B
$68M 0.93%
1,359,000
+267,000
+24% +$15.4M
XRAY icon
20
Dentsply Sirona
XRAY
$2.21B
$66.4M 0.91%
3,499,628
+852,856
+32% +$18M
PENN icon
21
PENN Entertainment
PENN
$2.28B
$65.4M 0.89%
3,298,268
+903,958
+38% +$17.8M
BHVN icon
22
Biohaven
BHVN
$2.26B
$62.5M 0.85%
1,672,298
+472,803
+39% +$22.1M
CYTK icon
23
Cytokinetics
CYTK
$10.5B
$61.7M 0.84%
1,312,000
-584,575
-31% -$30.4M
NVO
24
Novo Nordisk
NVO
$200B
$61.2M 0.84%
712,000
+147,000
+26% +$15.9M
SNY icon
25
Sanofi
SNY
$104B
$60.2M 0.82%
1,248,000
+668,000
+115% +$34M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $579M of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, up from 39% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.